The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Cidara Therapeutics | Common Stock | 171757107 | 3,273 | 1,640,514 | SH | SOLE | 1,640,514 | 0 | 0 | ||
| ESSA Pharma | Common Stock | 29668H708 | 5,762 | 1,709,848 | SH | SOLE | 1,709,848 | 0 | 0 | ||
| FibroGen | Common Stock | 31572Q808 | 4,831 | 130,646 | SH | SOLE | 130,646 | 0 | 0 | ||
| Gossamer Bio | Common Stock | 38341P102 | 110,027 | 6,553,116 | SH | SOLE | 6,553,116 | 0 | 0 | ||
| Immunic | Common Stock | 4525EP101 | 13,715 | 1,371,494 | SH | SOLE | 1,371,494 | 0 | 0 | ||
| Jounce Therapeutics | Common Stock | 481116101 | 1,765 | 529,965 | SH | SOLE | 529,965 | 0 | 0 | ||
| Morphic Holding | Common Stock | 61775R105 | 53,779 | 2,969,582 | SH | SOLE | 2,969,582 | 0 | 0 | ||
| ObsEva | Common Stock | H5861P103 | 8,325 | 999,364 | SH | SOLE | 999,364 | 0 | 0 | ||
| Paratek Pharmaceuticals | Common Stock | 699374302 | 11,234 | 2,600,410 | SH | SOLE | 2,600,410 | 0 | 0 | ||
| Pieris Pharmaceuticals | Common Stock | 720795103 | 2,560 | 750,741 | SH | SOLE | 750,741 | 0 | 0 | ||
| Prevail Therapeutics | Common Stock | 74140Y101 | 8,214 | 668,908 | SH | SOLE | 668,908 | 0 | 0 | ||
| Replimune Group | Common Stock | 76029N106 | 70,688 | 5,103,455 | SH | SOLE | 5,103,455 | 0 | 0 | ||
| Translate Bio | Common Stock | 89374L104 | 24,157 | 2,437,603 | SH | SOLE | 2,437,603 | 0 | 0 | ||
| Trevi Therapeutics | Common Stock | 89532M101 | 5,685 | 1,263,408 | SH | SOLE | 1,263,408 | 0 | 0 | ||